Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E6SX
|
||||
| Former ID |
DIB001038
|
||||
| Drug Name |
AZD-5069
|
||||
| Synonyms |
CXCR2 inhibitor (COPD), Astrazeneca
|
||||
| Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Discontinued in Phase 1 | [1] | ||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | High affinity interleukin-8 receptor B | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Chemokine signaling pathway | |||||
| Endocytosis | |||||
| Epithelial cell signaling in Helicobacter pylori infection | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| PANTHER Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | ||||
| Interleukin signaling pathway | |||||
| Pathway Interaction Database | IL8- and CXCR2-mediated signaling events | ||||
| Reactome | Chemokine receptors bind chemokines | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030696) | ||||
| REF 2 | Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.